Genentech announced topline results from its Phase III study program evaluating the etrolizumab in patients with moderate to severely active ulcerative colitis. Mixed results were seen…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.